Ron is a 58-year-old African-American man. He works as a regional branch manager for a large multinational bank. He is a former smoker and social drinker, with 1 adult son and 2 small grandchildren. He is involved in his community and, because of his busy schedule, exercises only sporadically. He is slightly overweight and takes chlorthalidone 25 mg QD for mild hypertension.
Ron presented to his primary care physician with a large, slow-growing, painful mass in his left leg. A biopsy revealed a myxoid round cell liposarcoma.
Following diagnosis, Ron underwent surgical resection. Pathology results showed 1- to 2-cm clean-margin myxoid round cell liposarcoma with >5% round cells and intermediate grade histology. During follow-up 8 months later, disease progression with local recurrence and metastatic disease with new lung metastases was identified. Ron underwent repeat surgical resection followed by anthracycline-based chemotherapy (anthracycline and ifosfamide) and radiotherapy. Fifteen months later, recurrence of metastatic lung lesions occurred.
Ron was given YONDELIS® 1.5 mg/m2 administered over 24 hours as an IV infusion every 3 weeks. Ron experienced an adverse reaction that resolved prior to the day of the next dose, indicating the need for a dose reduction. Ron continued on treatment with his YONDELIS® dose reduced to 1.2 mg/m2 every 3 weeks.